A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
Relapsed or Refractory T-cell Lymphomas
DRUG: BMS-986369
Number of participants with Adverse Events (AEs), Phase 1 participants, Up to 5 weeks after last dose of treatment|Number of participants with treatment-emergent adverse events (TEAEs), Phase 1 participants, Up to 5 weeks after last dose of treatment|Number of participants with Dose-Limiting Toxicity (DLT), Phase 1 participants, Up to 28 days after first dose|Number of participants with laboratory abnormalities, Phase 1 participants, Up to 5 weeks after last dose of treatment|Number of participants with vital sign abnormalities, Phase 1 participants, Up to 5 weeks after last dose of treatment|Number of participants with Electrocardiogram (ECG) abnormalities, Phase 1 participants, Up to 5 weeks after last dose of treatment|Eastern Cooperative Oncology Group Performance Status (ECOG PS), Phase 1 participants, Up to 5 weeks after last dose of treatment|Number of participants with Left Ventricular Ejection Fraction (LVEF) assessment abnormalities, Phase 1 participants, Up to 5 weeks after last dose of treatment|Number of participants with Physical Examination (PE) abnormalities, Phase 1 participants, Up to 5 weeks after last dose of treatment|Number of participants who achieve Objective Response (OR) as assessed by central review per international consensus response criteria for ATL, Phase 2: Adult T-cell Leukemia-Lymphoma (ATL) cohort

OR is defined as the achievement of Partial Response (PR), complete response unconfirmed (CRu), or Complete Response (CR), Up to 2 years after last does of treatment|Number of participants who achieve OR as assessed by central review per protocol-defined response criteria according to Lugano classification (Computed Tomography(CT)-based), Phase 2: Peripheral T-cell Lymphoma (PTCL) cohort

OR is defined as the achievement of PR or CR, Up to 2 years after last dose of treatment
Maximum observed plasma concentration (Cmax), Up to Day 8 of Cycle 2 (each cycle is 28 days)|Area under the plasma concentration time-curve (AUC), Up to Day 8 of Cycle 2 (each cycle is 28 days)|Time to peak (maximum) plasma concentration (Tmax), Up to Day 8 of Cycle 2 (each cycle is 28 days)|Number of participants with AEs, Phase 2 participants, Up to 5 weeks after last dose of treatment|Number of participants with TEAEs, Phase 2 participants, Up to 5 weeks after last dose of treatment|Number of participants with laboratory abnormalities, Phase 2 participants, Up to 5 weeks after last dose of treatment|Number of participants with vital sign abnormalities, Phase 2 participants, Up to 5 weeks after last dose of treatment|Number of participants with ECG abnormalities, Phase 2 participants, Up to 5 weeks after last dose of treatment|ECOG PS, Phase 2 participants, Up to 5 weeks after last dose of treatment|Number of participants with LVEF assessment abnormalities, Phase 2 participants, Up to 5 weeks after last dose of treatment|Number of participants with PE abnormalities, Phase 2 participants, Up to 5 weeks after last dose of treatment|Number of participants who achieve OR as assessed by central review per international consensus response criteria for ATL, ATL participants

OR is defined as the achievement of PR, CRu, or CR, Up to 4 years after last dose of treatment|Number of participants who achieve OR as assessed by investigator per international consensus response criteria for ATL, ATL participants

OR is defined as the achievement of PR, CRu, or CR, Up to 4 years after last dose of treatment|Number of participants who achieve OR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based)., PTCL participants

OR is defined as the achievement of PR or CR, Up to 4 years after last dose of treatment|Number of participants who achieve OR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based)., PTCL participants

OR is defined as the achievement of PR or CR, Up to 4 years after last dose of treatment|Number of participants who achieve disease control as assessed by central review per international consensus response criteria for ATL, ATL participants

Disease control is considered to be stable disease (SD), PR, CRu, or CR, Up to 4 years after last dose of treatment|Number of participants who achieve disease control as assessed by investigator per international consensus response criteria for ATL, ATL participants

Disease control is considered to be SD, PR, CRu, or CR, Up to 4 years after last dose of treatment|Number of participants who achieve CR as assessed by central review per international consensus response criteria for ATL, ATL participants, Up to 4 years after last dose of treatment|Number of participants who achieve CR as assessed by investigator per international consensus response criteria for ATL, ATL participants, Up to 4 years after last dose of treatment|Time to response (TTR) as assessed by central review per international consensus response criteria for ATL, ATL participants, Up to 4 years after last dose of treatment|TTR as assessed by investigator per international consensus response criteria for ATL, ATL participants, Up to 4 years after last dose of treatment|Duration of response (DOR) as assessed by central review per international consensus response criteria for ATL, ATL Participants, Up to 4 years after last dose of treatment|DOR as assessed by investigator per international consensus response criteria for ATL, ATL Participants, Up to 4 years after last dose of treatment|Progression Free Survival (PFS) as assessed by central review per international consensus response criteria for ATL, ATL participants, Up to 4 years after last dose of treatment|PFS as assessed by investigator per international consensus response criteria for ATL, ATL participants, Up to 4 years after last dose of treatment|Number of participants who achieve disease control as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants

Disease control is considered to be SD, PR or CR, Up to 4 years after last dose of treatment|Number of participants who achieve disease control as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants

Disease control is considered to be SD, PR or CR, Up to 4 years after last dose of treatment|Number of participants who achieve CR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|Number of participants who achieve CR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|TTR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|TTR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|DOR as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|DOR as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|PFS as assessed by central review per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|PFS as assessed by investigator per protocol defined response criteria according to Lugano classification (CT-based), PTCL participants, Up to 4 years after last dose of treatment|Time to next treatment (TTNT), From the date of last dose until the date of death, lost to follow-up, withdrawal of consent from the entire study, time to next treatment or the end of the trial, whichever occurs first, assessed up to 2 years after end of treatment.|Overall survival (OS), From the date of last dose until the date of death, lost to follow-up, withdrawal of consent from the entire study, or the end of the trial, whichever occurs first, assessed up to 2 years after end of treatment.
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).